

AssayMax™ Human TGF-beta-1 ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μ l of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 2 hours.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 20 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
∞								
7								
9								
.c								
4								
ю								
2								
1								
	Ą	В	3	Q	3	Ŧ	9	I

AssayMax™ Human TGF-beta-1 ELISA Kit

Catalog No. ET3102-1
Sample insert for reference use only

Introduction

Transforming growth factor beta-1 (TGF-beta-1) is one of the transforming growth factor beta (TGF-beta) family cytokines and exerts pleiotropic effects upon a wide variety of cell types. TGF-beta-1 is of fundamental importance in the development, physiology, and pathology of the vascular system (1). It is known to maintain a balance between apoptosis and cellular dysfunction (2). Over-expression of TGF-beta-1 is the cellular change associated with abnormal extracellular matrix deposition in nodular glomerulosclerosis (3) and may be a pathogenetic mechanism in tumor progression (4). High serum levels of TGF-beta-1 probably mirror an anti-inflammatory response, which might play a role in controlling the systemic immune response (5).

Principle of the Assay

The AssayMax™ Human TGF-beta-1 ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of TGF-beta-1 in human cell culture supernatant samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human TGF-beta-1 in approximately 5 hours. A murine monoclonal antibody specific for human TGF-beta-1 has been pre-coated onto a 96-well microplate with removable strips. TGF-beta-1 in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human TGF-beta-1, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial, the biotinylated antibody vial, and the standard diluent vial before opening and using contents.

- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human TGF-beta-1 Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a murine monoclonal antibody against human TGF-beta-1.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human TGF-beta-1 Standard: Human TGF-beta-1 in a buffered protein base (4 ng, lyophilized).
- **Biotinylated Human TGF-beta-1 Antibody (30x):** A 30-fold concentrated biotinylated polyclonal antibody against human TGF-beta-1 (180 µl).
- EIA Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Standard Diluent (1x): A buffered protein base with stabilizer (2 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Standard Diluent (1x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

 Cell Culture Supernatant: Centrifuge cell culture media at 1500 rpm for 10 minutes at 4°C to remove debris and collect supernatant. If necessary, dilute samples into EIA Diluent; user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested)				
	100x		10000x		
A) 4 μl sample : 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl.		 A) 4 μl sample : 396 μl buffer (100x) B) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl. 			
	1000x		100000x		
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution Assuming the needed volume is less than	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution		
	or equal to 240 μl.		Assuming the needed volume is less than or equal to 240 μl.		

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- EIA Diluent Concentrate (10x): Dilute the EIA Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved. Store for up to 30 days at 2-8°C.
- Human TGF-beta-1 Standard: Reconstitute the Human TGF-beta-1 Standard (4 ng) with 0.5 ml of Standard Diluent to generate an 8 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (8 ng/ml) 2-fold with equal volume of EIA Diluent to produce 4, 2, 1, 0.5,

0.25, 0.125, and 0.063 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and **used within 30 days**.

Standard Point	Dilution	[TGF-beta-1] (ng/ml)
P1	1 part Standard (8 ng/ml) + 1 part EIA Diluent	4.0
P2	1 part P1 + 1 part EIA Diluent	2.0
Р3	1 part P2 + 1 part EIA Diluent	1.0
P4	1 part P3 + 1 part EIA Diluent	0.5
P5	1 part P4 + 1 part EIA Diluent	0.25
P6	P6 1 part P5 + 1 part EIA Diluent	
P7	1 part P6 + 1 part EIA Diluent	0.063
P8	· · ·	

- Biotinylated Human TGF-beta-1 Antibody (30x): Spin down the antibody briefly and dilute the desired amount of the antibody 30-fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the
 desired amount of the conjugate 100-fold with EIA Diluent to produce a
 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them
 immediately to the foil pouch with desiccants inside. Reseal the pouch
 securely to minimize exposure to water vapor and store in a vacuum
 desiccator.
- Add 50 µl of Human TGF-beta-1 Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on

absorbent material to completely remove the liquid. If washing manually, wash five times with 200 μ l of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 μ l of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.

- Add 50 µl of Biotinylated Human TGF-beta-1 Antibody to each well.
 Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 20 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data

 The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	4.0	2.034	2.005
ΓI	4.0	1.976	2.003
P2	2.0	1.375	1.334
PZ	2.0	1.293	1.554
P3	1.0	0.839	0.848
PS	1.0	0.857	0.040
P4	0.5	0.519	0.511
Г4		0.503	0.511
P5	0.25	0.300	0.305
PO		0.310	0.303
P6	0.125	0.199	0.194
PO	0.125	0.189	0.194
P7	0.063	0.130	0.133
F/	0.003	0.136	0.133
P8	0.0	0.063	0.065
го	P8 0.0	0.067	0.005

Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Performance Characteristics

- This assay recognizes both natural and recombinant human TGF-beta-1.
- The minimum detectable dose of human TGF-beta-1 as calculated by 2SD from the mean of a zero standard was established to be 31 pg/ml.
- Intra-assay precision was determined by testing three reference control samples twenty times in one assay.
- Inter-assay precision was determined by testing three reference control samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Pred	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	6.9%	6.4%	6.1%	11.5%	10.8%	10.3%
Average CV (%)	6.5%				10.9%	

Spiking Recovery

 Recovery was determined by spiking one reference control sample with different TGF-beta-1 concentrations.

Sample	Unspiked Sample (ng/ml)	Spiking Value (ng/ml)	Expected	Observed	Recovery (%)
	0.092	1.885	1.977	2.101	106%
1		0.498	0.590	0.653	111%
		0.122	0.214	0.228	107%
Average Recovery (%)					108%

Troubleshooting

Issue	Causes	Course of Action		
	Use of improper components	Check the expiration date listed before use. Do not interchange components from different lots.		
Precision	Improper wash step	Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique.		
Low	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.		
	Inconsistent volumes loaded into wells	Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.		

	Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions. 		
	Improperly sealed microplate	Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures. Check that three desiccants are inside the microplate pouch prior to sealing.		
gnal	Microplate was left unattended between steps	Each step of the procedure should be performed uninterrupted.		
S	Omission of step	 Consult the provided procedure for complete list of steps. 		
High	Steps performed in incorrect order	Consult the provided procedure for the correct order.		
Unexpectedly Low or High Signal Intensity	Insufficient amount of reagents added to wells	Check pipette calibration.Check pipette for proper performance.		
<u>≥</u> ⊆	Wash step was skipped	 Consult the provided procedure for all wash steps. 		
Ĕ	Improper wash buffer	 Check that the correct wash buffer is being used. 		
xbec	Improper reagent preparation	 Consult reagent preparation section for the correct dilutions of all reagents. 		
Une	Insufficient or prolonged incubation periods	Consult the provided procedure for correct incubation time.		
Deficient Standard Curve Fit	Non-optimal sample dilution	Sandwich ELISA: If samples generate OD values higher than the highest standard point (P1), dilute samples further and repeat the assay. Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay. User should determine the optimal dilution factor for samples.		
da	Contamination of	 A new tip must be used for each addition of different 		
ia n	reagents	samples or reagents during the assay procedure.		
t Si	Contents of wells evaporate	 Verify that the sealing film is firmly in place before placing the assay in the incubator or at room temperature. 		
Deficien	Improper pipetting	Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.		
	Insufficient mixing of reagent dilutions	Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.		

References

- (1) Ghosh J et al. (2005) Cardiovasc Pathol. 14(1):28-36.
- (2) Jacob T et al. (2005) J Vasc Surg. 41(3):523-30.
- (3) Zhao HL et al. (2004) Am J Kidney Dis. 44(6):1039-49.
- (4) Maluccio M et al. (2003) Transplantation. 76(3):597-602.
- (5) Widhe M et al. (2002) Immunology. 107(1):46-55.

Version 4.8R